Charles M Atisso

Suggest Changes
Learn More
BACKGROUND Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients with type 2 diabetes. In a head-to-head trial,(More)
In addition, three sentences require revision. Page 2165, RESULTS section, the sentence “Ten (1.8%) patients randomized to dulaglutide developed treatment-emergent dulaglutide ADAs at least once(More)
The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on(More)
  • 1